Monroy-Álvarez CJ, Covarrubias-Gómez A, Garduño-López AL

Language: Spanish
References: 29
Page: 193-200
PDF size: 250.83 Kb.

ABSTRACT

Chronic kidney disease is nowadays considered as a major health issue. Its prevalence increases with age. The prevalence of chronic kidney disease in Mexico has increase during the last decades due the increase in the number of subjects with diabetes mellitus and other chronic degenerative diseases. A percentage of these individuals will eventually undergo to a surgical procedure and they may need analgesic relief from the resultant acute postoperative pain. Therefore it is important for the clinician to identify the pharmacological issues related to the dysfunction of normal kidney physiology and the impact of these changes in the action of analgesic drugs.

REFERENCES

1. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278-285.

2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047.

3. Graves JW. Diagnosis and management of chronic kidney disease. Mayo Clin Proc. 2008;83:1064-1069.

4. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39:S1-S266.

5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., 2013;3:1-150. Disponible en Internet con indicaciones para referenciar en: [http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf]

6. Verbeeck R. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757-773.

7. Ryzner KL. Evaluation of aminoglycoside clearance using the modification of diet in renal disease equation versus the Cockcroft-Gault equation as a marker of glomerular filtration rate. Ann Pharmacother. 2010;44:1030-1037.

8. Davison S, Jhangri G. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage. 2010;39:477-485.

9. Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997;32:30-57.

10. Levy G, Giacomini KM. First-pass effects in health and disease: pharmacokinetics studies on dextropropoxyphene. En: Prescott LF, Nimmo WS. Drug absorption. Proc Edinburgh Int Conf. Ed MTP. Lancaster, Reino Unido. 1981, pp. 115-122.

11. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism. Br J Anaesth. 1993;71:282-290.

12. Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A. Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol. 2008;19:1352-1359.

13. Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. ChemBiol Interact. 2003;145:117-137.

14. Bricker NS, Morrin PAF. The pathologic physiology of chronic Bright’s disease: an exposition of the “intact nephron hypothesis”. J Am Soc Nephrol. 1997;8:1470-1476.

15. Tett SE, Kirkpatrick CMJ, Gross AS. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003;42:1193-1211.

16. Kurella M, Bennett W. Analgesia in Patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42:217-228.

17. Davison S. Pain in hemodialysis patients. Prevalence, etiology, severity and management. Am J Kidney Dis. 2003;42:1239-1247.

18. Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain. 2005;6:137-148.

19. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendation for practice. J Pain Palliat Care Pharmacother. 2007;21:5-16.

20. Kafkia T, Chamney M, Drinkwater A, Pegoraro M, Sedgewick J. Pain in chronic kidney disease: prevalence, cause and management. J Ren Care. 2011;37:114-122.

21. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat Med. 2006;4:977-992.

22. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011;25:525-552.

23. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID Use and Progresion of Chronic Kidney Disease. Am J Med. 2007;120:280.e1-280.e7.

24. Parmar MS, Parmar KS. Management of acute and postoperative pain in chronic kidney disease. [Internet] [v3; ref status: indexed. Disponible en: http://f1000r.es/10f] F1000Research 2013, 2: 28 (doi: 10.12688/f1000research.2-28.v3).

25. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth. 2002;88:199-214.

26. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27:417-433.

27. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21:5-16.

28. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428-450.

29. Haanpää ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clinic Proceedings. 2010;85:S15-S25.